Cytek Biosciences CTKB Institutional Ownership

Updated Oct 11, 2026

Cytek Biosciences, Inc. (NASDAQ:CTKB) was reported as a holding by 156 institutional investors in 13F filings for the quarter ended June 30, 2026.

• These investors held 62.75% of Cytek Biosciences' outstanding shares at the end of Q2 2026, down from 65.87% in Q1 2026.
• Total shares held in Cytek Biosciences fell 4.11% from Q1 2026, while the number of holders was unchanged from Q2 2025.
• Looking at the 156 holders of CTKB individually, 75 added to their positions, 64 reduced their stakes and 17 left their positions unchanged.
• In total, institutional investors held 81.57Mn shares of Cytek Biosciences at the end of Q2 2026, down 3.5Mn from the prior quarter and up 3.9Mn from a year earlier.
• BlackRock, Inc. led 13F holders of CTKB with 9.58Mn shares as of June 30, 2026, or 7.37% of shares outstanding.
• The biggest increases in CTKB positions during Q2 2026 came from Millennium Management LLC (+3.05Mn shares), Boston Partners (+1.86Mn shares), Acadian Asset Management LLC (+977.06K shares), Arrowstreet Capital, Limited Partnership (+653.92K shares) and Susquehanna International Group, LLP (+625.7K shares).
• The biggest cuts to CTKB positions during Q2 2026 came from BlackRock, Inc. (-7.43Mn shares), State Street Corp (-1.56Mn shares), Vanguard Portfolio Management LLC (-1.17Mn shares), Morgan Stanley (-1.02Mn shares) and Topline Capital Management, LLC (-781.03K shares).
• According to Business Quant data, the leading holders of CTKB for Q2 2026 were BlackRock, Inc. (9.58Mn shares), Millennium Management LLC (9.34Mn shares), Boston Partners (7.66Mn shares), HHLR Advisors, LTD. (6.66Mn shares), Topline Capital Management, LLC (6.28Mn shares), Vanguard Capital Management LLC (4.94Mn shares), Geode Capital Management, LLC (3.06Mn shares), Dimensional Fund Advisors LP (2.62Mn shares), State Street Corp (2.57Mn shares) and Goldman Sachs Group Inc (2.17Mn shares).